As a biomarker, we demonstrated that NDRG4 DNA hypermethylation is associated with negative prognostic factors, such as tumor size, p53 overexpression and the presence of lymph node metastasis, in breast cancer patients. The gene discussed is TP53; the disease is breast cancer.